Change to Ukrainian interface versionChange to English interface versionChange to Russian interface versionHome pageClear last query resultsHelp page
Search for specific termsBrowse by subject categoryBrowse alphabetical list of titlesBrowse by organizationBrowse special topic issues

close this bookEffective Approaches for the Prevention of HIV/Aids in Woman (PAHO, WHO; 1995; 62 pages)
View the documentExecutive summary
View the document1. Introduction
View the document2. Opening of the meeting
close this folder3. Women and HIV/AIDS
View the document3.1 The global epidemiological situation
View the document3.2 Current state of vaccine development
View the document3.3 Current research on female-controlled methods
View the document3.4 An overview of key social and economic factors contributing to women’s vulnerability to HIV/AIDS
View the document3.5 Consultation for policy-makers on women and AIDS in preparation for the Fourth World Conference on Women
Open this folder and view contents4. Effective approaches to prevention of HIV/AIDS in women
Open this folder and view contents5. Experiences from other fields: implications for HIV/AIDS prevention
Open this folder and view contents6. Future directions: national policies and large-scale programmes
View the document7. Overall conclusions
View the documentAppendix 1 - Agenda
View the documentAppendix 2 - List of participants
View the documentAppendix 3 - List of background papers
View the documentAppendix 4 - Selected reading list

3.2 Current state of vaccine development

Dr J. Esparza, Chief of the GPA Vaccine Development unit, summarized developments in this field. The basic vaccine types (e.g. whole inactivated virus, live attenuated virus) were presented, as were problems in HIV vaccine development such as the lack of knowledge about immune correlates of vaccine protection and possible and observed virus variability. Dr Esparza also described the phases of vaccine development. He strongly emphasized that we can certainly not expect to see an HIV vaccine before the year 2000 (and this being a best-case scenario): the first efficacy trials will probably start in 1996-1997 and will last for two to three years; additional trials would be required; and licensing, manufacturing and distribution is often a lengthy process.

to previous section to next section

[Ukrainian]  [English]  [Russian]